Facebook X-twitter Youtube Instagram Linkedin

This Webinar has Concluded. Click Here to Watch the Recap

Cannabis at a Crossroads: What DEA Rescheduling Really Means for the U.S.

Medical marijuana is now Schedule III, but only in a very narrow lane. On October 22, CannDelta’s Dr. Lucas McCann and attorney Sahar Ayinehsazian of AY Strauss LLP break down what the April order changed, what it didn’t, and the moves operators should make before the end of 2026.

  • SIGN UP for the DEA Webinar and be among the first to watch when it goes live.
Register Now

The Headlines Said Rescheduling. The Fine Print Says Something Much Narrower.

On April 22, 2026, Acting Attorney General Todd Blanche signed the order moving marijuana to Schedule III. It took effect on April 28. But only two lanes moved: FDA-approved drug products and marijuana produced under a state medical marijuana license. Adult-use cannabis, unlicensed crops, and bulk extracts outside those two lanes remain strictly in Schedule I. The hearing has concluded, the industry is waiting on adult-use, and the DEA is reviewing its first wave of registrations. Meanwhile, operators are facing real decisions on 280E, interstate commerce, export, banking, and investor relations. Getting them wrong can put your bank account on pause, throw off your tax planning, or stall a deal. Dr. Lucas McCann sits down with cannabis attorney Sahar Ayinehsazian of AY Strauss LLP. They separate confirmed changes from industry speculation and show you exactly how to plan while so much remains unanswered.

Reserve Your Spot Today!

Webinar Starts In.....

Days
Hours
Minutes
Seconds
Register Now

What You'll Walk Away With

  1. What the April Order Actually Changed
    Understand which products are now Schedule III and why the scope is narrow. Learn what stays in Schedule I, including adult-use and bulk cannabis, to avoid building strategies on headlines alone.

  2. Why Applying Doesn’t Make You Federally Compliant
    Submitting a DEA application does not guarantee compliance. Discover if you need separate facility registrations and how Forms 225 and 224 apply to cultivators and dispensaries.

  3. What Operators Are Seeing Inside the DEA Review
    Get a firsthand look at DEA inspections and reviews. Learn why the agency is currently in a learning phase rather than an enforcement phase, and discover how operators can leverage this window.

  4. 280E Tax Planning
    Learn when medical operators can adopt standard accounting for 280E. Understand why dual-use businesses must separate their books and why past 280E payments will not be refunded.

  5. The DEA Crop Purchase Requirement
    The DEA must take possession of crops from registered manufacturers, returning them with a $113 per kg fee. Explore the unresolved questions around pricing, freshness, and inspections before they impact your margins.

  6. Why Interstate Commerce Is Not Here Yet
    The April order does not authorize interstate commerce. Review the remaining roadblocks, including state vertical integration rules, complex packaging requirements, shipping hurdles, and highway enforcement.

  7. The Export Opportunity and Its Realistic Timeline
    Understand how EU GMP and GACP certifications impact exports. Discover what CannDelta is seeing from Canadian exporters and learn why U.S. exports are likely a year away rather than six months.

  8. Banking, Investors and Contracts
    Learn why export plans could pause your bank accounts and how to handle investor questions on rescheduling. Get the exact updates your contracts and liability caps need before a market standard exists.

  9. Missed the 60-Day Window?
    Find out why it is still safe to apply and hear exactly what late applicants are experiencing during current DEA reviews.

  10. What to Watch Before Year-End
    Hear predictions for the next three months, including the upcoming hearing decision. See what Lucas expects for the first registration approvals by late 2026 and the 280E guidance to watch for.

Meet the Experts

Lucas McCann in New York outside of the CannDelta office.

Dr. Lucas C. McCann, Ph.D.

Co-Founder and Chief Scientific Officer, CannDelta

Dr. Lucas McCann provides scientific business strategy oversight on all CannDelta projects. As a co-founder of CannDelta, he has helped launch over 300 licensed businesses in the cannabis sector in the U.S., Canada, and overseas. A medicinal and synthetic organic chemist by training, a former federal government employee, and a small-business consultant, Lucas helps clients with business strategy, planning, and navigating regulatory frameworks and license applications. He is a dynamic public speaker who regularly engages with local and international media, and he has published multiple peer-reviewed journal articles and a university textbook.

Sahar Ayinehsazian

Attorney, AY Strauss LLP

Sahar has worked in cannabis for nearly 11 years. She advises operators on regulatory, corporate, and transactional matters as the industry moves toward federal oversight. 

Frequently Asked Questions

When is the webinar?
The webinar releases on October 22, 2026. Register now and we’ll let you know as soon as it’s live.
U.S. cannabis operators of any size who need to know what Schedule III means in practice, including cultivators, manufacturers, processors, and dispensaries. It is especially relevant for dual-use operators, anyone who has applied or is thinking about applying for DEA registration, and businesses planning for export or interstate expansion.
Not in the way many headlines suggested. The April order covers a much narrower lane than most people realize. Lucas and Sahar break down exactly what moved to Schedule III and what didn’t.
It’s one of the most common assumptions in the industry right now, and it isn’t that simple. Sahar walks through the questions every operator should be asking about their status.
You’re not alone. Sahar shares what her clients who applied after the window are experiencing with the DEA right now.
Registered manufacturers face a requirement that most operators haven’t planned for. Find out how it works and the open questions that could affect your pricing, your product, and your operations.
It depends on how your operation is set up. Learn who may be able to change their approach, what dual-use operators need to think about, and what to expect when it comes to past payments.
This is the question Lucas expects to be on everyone’s mind next. Hear what still stands in the way and what federal and state governments would need to sort out first.
Lucas shares his realistic timeline, what Canadian exporters can teach U.S. operators, and the certifications you’ll need in place before you can ship.
It could if you don’t approach it carefully. Sahar explains why one conversation with your bank deserves a plan, along with how to prepare for questions from your investors.
About an hour of candid conversation between a cannabis scientist and a cannabis attorney.
Yes. CannDelta supports operators with DEA registration, mock DEA inspections, SOP reviews, and EU GMP and GACP certification. We make sure the protocols written in your SOPs match exactly what is happening in your facility.

Get Ready Before the First Wave of Decisions Lands

CannDelta expects the DEA’s first registration decisions before the end of 2026. Whether you are waiting on your application, thinking about applying late, or planning for export, now is the time to get ahead.

Watch the webinar on October 22

Register now to hear Lucas and Sahar separate the facts from the speculation.
Register for the Webinar

Need help now?

Talk to CannDelta about DEA registration, mock inspections, SOP reviews, and certification.
Book a Free Consultation
Or call 1 (877) 274-6777